DNA vs. NWBO

In the year-to-date period, DNA achieves a -20.16% return, which is significantly lower than NWBO's 18.52% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Ginkgo Bioworks Holdings, Inc. (DNA) and Northwest Biotherapeutics, Inc. (NWBO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current DNA Sharpe Ratio is -0.68, which is lower than the NWBO Sharpe Ratio of -0.34. The chart below compares the historical Sharpe Ratios of DNA and NWBO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither DNA nor NWBO has paid dividends to shareholders.

The maximum DNA drawdown since its inception was -99.10%, roughly equal to the maximum NWBO drawdown of -99.99%. Use the drawdown chart below to compare losses from any high point for DNA and NWBO. For additional features, visit the drawdowns tool.

The current volatility for Ginkgo Bioworks Holdings, Inc. (DNA) is 32.07%, while Northwest Biotherapeutics, Inc. (NWBO) has a volatility of 73.20%. This indicates that DNA experiences smaller price fluctuations and is considered to be less risky than NWBO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Ginkgo Bioworks Holdings, Inc. and Northwest Biotherapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.